

Bone Biologics Corporation
2 Burlington Woods Drive, Suite 100
Burlington, MA 01803

August 22, 2024

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Robert Augustin

Re: **Bone Biologics Corporation**
Registration Statement on Form S-3
File No. 333-281494

Ladies and Gentlemen:

In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Bone Biologics Corporation, a Delaware corporation, hereby requests that the effectiveness of the registration statement on Form S-3 (File No. **333-281494**), filed with the U.S. Securities and Exchange Commission on August 12, 2024, be accelerated so that the registration statement becomes effective at 4:00 p.m. Eastern Time on August 26, 2024 or as soon thereafter as practicable.

If you have any questions or comments, please contact Alexander R. McClean of Harter Secrest & Emery at (585) 231-1248.

Very truly yours,

Bone Biologics Corporation

By: */s/ Jeffrey Frelick*

Jeffrey Frelick
President and Chief Executive Officer
